Kailera Therapeutics (KLRA) Stock Insights
KLRA$13.12-0.01 -0.08%
$1.70B
Market Cap
-7.30
P/E
—
Forward P/E
72
Score
Kailera Therapeutics (KLRA) Stock Insights
KLRA price $13.12 -0.01 -0.08%
- Ticker
- KLRA
- Price
- $13.12
- Change
- -0.01 -0.08%
- Market cap ?
- $1.70B
- P/E ?
- -7.30
- Dividend yield ?
- 0.00%
- Beta ?
- 0.50
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 72
- Value
- 70
- Quality
- 47
- Growth
- 100
Stocklytics score rationale: value 70, quality 47, growth 100.
Financials
| 2025 |
|---|
| 0 |
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1…
Fair value
KLRA fair value Not meaningful. Price $13.12.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Not meaningful
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-04 | — | -1.01 | — | — |
| 2026-08-12 | -1.09 | -0.90 | — | — |
| 2026-05-26 | -3,650.00 | -0.78 | — | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-07 | Nicholson Nur | Buy | 220.00K | $16.23 | 3.57M |
| 2026-08-31 | Nicholson Nur | Other | 0 | — | — |
| 2026-07-06 | Tregoning Kathleen | Buy | 175.00K | $23.30 | 4.08M |
| 2026-06-29 | Tregoning Kathleen | Other | 0 | — | — |
| 2026-06-09 | Renaud Ronald C JR | Sell | 38.09K | $5.25 | 199.99K |
| 2026-06-09 | Renaud Ronald C JR | Buy | 38.09K | $5.25 | 199.99K |
| 2026-04-20 | RTW INVESTMENTS, LP | Buy | 500.00K | $16.00 | 8.00M |
| 2026-04-20 | RTW INVESTMENTS, LP | Buy | 10.28M | — | — |
| 2026-04-20 | RTW INVESTMENTS, LP | Sell | 8.25M | — | — |
| 2026-04-20 | RTW INVESTMENTS, LP | Sell | 2.03M | — | — |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Buy | 9.48M | — | — |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Buy | 2.03M | — | — |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Sell | 4.97M | — | — |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Sell | 708.81K | — | — |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC | Buy | 8.40M | $16.00 | 134.38M |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC | Buy | 17.86M | — | — |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC | Sell | 17.86M | — | — |
| 2026-04-20 | Koppel Adam | Buy | 1.56M | $16.00 | 25.00M |
| 2026-04-20 | Koppel Adam | Buy | 4.15M | — | — |
| 2026-04-20 | Koppel Adam | Buy | 16.88M | — | — |
| 2026-04-20 | Koppel Adam | Sell | 16.88M | — | — |
| 2026-04-20 | Koppel Adam | Sell | 4.15M | — | — |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC | Buy | 1.56M | $16.00 | 25.00M |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC | Buy | 4.15M | — | — |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC | Buy | 16.88M | — | — |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC | Sell | 16.88M | — | — |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC | Sell | 4.15M | — | — |
| 2026-04-20 | Kaplan Andrew T. | Buy | 8.40M | $16.00 | 134.38M |
| 2026-04-20 | Kaplan Andrew T. | Buy | 17.86M | — | — |
| 2026-04-20 | Kaplan Andrew T. | Sell | 17.86M | — | — |
| 2026-04-16 | Koppel Adam | Buy | 38.30K | $16.00 | 612.80K |
| 2026-04-16 | Kaplan Andrew T. | Buy | 38.30K | $16.00 | 612.80K |
| 2026-04-16 | Cloghessy Paula | Buy | 60.00K | $16.00 | 960.00K |
| 2026-04-16 | Akamine Scott | Buy | 60.00K | $16.00 | 960.00K |
| 2026-04-16 | Renaud Ronald C JR | Buy | 300.00K | $16.00 | 4.80M |
| 2026-04-16 | Burgess Paul D. | Buy | 100.00K | $16.00 | 1.60M |
| 2026-04-16 | MILLIGAN JOHN F | Buy | 38.30K | $16.00 | 612.80K |
| 2026-04-16 | Coleman Jamie Beth | Buy | 75.00K | $16.00 | 1.20M |
| 2026-04-16 | MACKAY MARTIN | Buy | 38.30K | $16.00 | 612.80K |
| 2026-04-16 | Wasserman Scott M. | Buy | 100.00K | $16.00 | 1.60M |
| 2026-04-16 | Hite Christopher | Buy | 38.30K | $16.00 | 612.80K |
| 2026-04-16 | Clyburn Frank | Buy | 38.30K | $16.00 | 612.80K |
| 2026-04-16 | Pagan Douglas W. | Buy | 100.00K | $16.00 | 1.60M |
| 2026-04-16 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Other | 0 | — | — |
| 2026-04-16 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Other | 9.48M | — | — |
| 2026-04-16 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Other | 2.03M | — | — |
| 2026-04-16 | Koppel Adam | Other | 16.88M | — | — |
| 2026-04-16 | Koppel Adam | Other | 4.15M | — | — |
| 2026-04-16 | BAIN CAPITAL INVESTORS LLC | Other | 17.86M | — | — |
| 2026-04-16 | Bain Capital Life Sciences Investors, LLC | Other | 16.88M | — | — |
| 2026-04-16 | Bain Capital Life Sciences Investors, LLC | Other | 4.15M | — | — |
| 2026-04-16 | Kaplan Andrew T. | Other | 17.86M | — | — |
| 2026-04-16 | Burgess Paul D. | Other | 191.44K | $5.25 | 1.01M |
| 2026-04-16 | Burgess Paul D. | Other | 325.49K | $7.24 | 2.36M |
| 2026-04-16 | Wasserman Scott M. | Other | 427.96K | $5.25 | 2.25M |
| 2026-04-16 | Wasserman Scott M. | Other | 147.32K | $7.24 | 1.07M |
| 2026-04-16 | Pagan Douglas W. | Other | 700.80K | $10.09 | 7.07M |
| 2026-04-16 | Coleman Jamie Beth | Other | 357.56K | $5.40 | 1.93M |
| 2026-04-16 | Coleman Jamie Beth | Other | 268.33K | $7.24 | 1.94M |
| 2026-04-16 | RTW INVESTMENTS, LP | Other | 8.25M | — | — |
| 2026-04-16 | RTW INVESTMENTS, LP | Other | 2.03M | — | — |
| 2026-04-16 | MACKAY MARTIN | Other | 170.19K | $11.56 | 1.97M |
| 2026-04-16 | Liu Yuting | Other | 0 | — | — |
| 2026-04-16 | Hite Christopher | Other | 81.05K | $5.40 | 437.66K |
| 2026-04-16 | Hite Christopher | Other | 89.15K | $7.24 | 645.42K |
| 2026-04-16 | Cloghessy Paula | Other | 86.15K | $5.25 | 452.29K |
| 2026-04-16 | Cloghessy Paula | Other | 95.35K | $5.40 | 514.89K |
| 2026-04-16 | Cloghessy Paula | Other | 230.73K | $7.24 | 1.67M |
| 2026-04-16 | Renaud Ronald C JR | Other | 287.17K | $5.25 | 1.51M |
| 2026-04-16 | Renaud Ronald C JR | Other | 1.33M | $7.24 | 9.64M |
| 2026-04-16 | Clyburn Frank | Other | 170.19K | $7.24 | 1.23M |
| 2026-04-16 | Akamine Scott | Other | 143.67K | $5.25 | 754.28K |
| 2026-04-16 | Akamine Scott | Other | 194.00K | $7.24 | 1.40M |
| 2026-04-16 | MILLIGAN JOHN F | Other | 285.31K | $5.25 | 1.50M |
| 2026-04-16 | MILLIGAN JOHN F | Other | 313.82K | $7.24 | 2.27M |
| 2026-04-16 | CANADA PENSION PLAN INVESTMENT BOARD | Other | 5.00M | — | — |
| 2026-04-16 | Stuart Partners, LLC | Other | 1.43M | — | — |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 102. Ownership 99.40%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 26.26M | New | New | 578.41M |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 22.58M | New | New | 497.51M |
| RTW INVESTMENTS, LP | 10.78M | New | New | 237.41M |
| CANADA PENSION PLAN INVESTMENT BOARD | 7.30M | New | New | 160.92M |
| ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | 5.17M | New | New | 113.92M |
| FMR LLC | 3.97M | New | New | 87.48M |
| BLACKROCK, INC. | 3.93M | New | New | 86.55M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.53M | New | New | 77.86M |
| CITADEL ADVISORS LLC | 3.24M | New | New | 71.39M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.21M | New | New | 70.68M |
| WELLINGTON MANAGEMENT GROUP LLP | 2.92M | New | New | 64.31M |
| ROYALTY PHARMA SUB-MANAGER, LLC | 2.46M | New | New | 54.09M |
| SIREN, L.L.C. | 2.21M | New | New | 48.78M |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.69M | New | New | 37.32M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.65M | New | New | 36.40M |
| GEODE CAPITAL MANAGEMENT, LLC | 1.13M | New | New | 24.97M |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 1.10M | New | New | 24.23M |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 1.10M | New | New | 24.23M |
| TRAILS EDGE CAPITAL PARTNERS, LP | 984.79K | New | New | 21.69M |
| UBS GROUP AG | 972.68K | New | New | 21.43M |
| JUPITER TOPCO LLC | 970.86K | New | New | 21.34M |
| STATE STREET CORP | 868.16K | New | New | 19.13M |
| AMERIPRISE FINANCIAL INC | 821.33K | New | New | 18.09M |
| DEEP TRACK CAPITAL, LP | 700.00K | New | New | 15.42M |
| EVENTIDE ASSET MANAGEMENT, LLC | 616.72K | New | New | 13.59M |
Insights · Dividends · Forecast · Financials · Learn